| Combination of | |
|---|---|
| Netupitant | NK1 receptor antagonist |
| Palonosetron | 5-HT3 receptor antagonist |
| Clinical data | |
| Trade names | Akynzeo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614053 |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth,intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG |
|
Netupitant/palonosetron, sold under the brand nameAkynzeo, is afixed-dose combination medication used for the prevention of acute and delayedchemotherapy-induced nausea and vomiting.[7][9] It is marketed and distributed byHelsinn Therapeutics.Netupitant is anNK1 receptor antagonist andpalonosetron is a5-HT3 receptor antagonist.[10]
The capsules containnetupitant andpalonosetron hydrochloride. The intravenous version is a combination offosnetupitant chloride hydrochloride andpalonosetron hydrochloride.[11][7][8]
Netupitant/palonosetron may be contraindicated during pregnancy.[12][1][13]
The most common side effects include headache, weakness, fatigue, upset stomach,constipation, and skin redness.[7] The overall profile of adverse effects is comparable to that of palonosetron (seePalonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[12]
Netupitant/palonosetron was approved for use in the United States in October 2014.[14] It was approved for use in the European Union in May 2015.[8] The intravenous version, which contains the prodrugfosnetupitant in place of netupitant, was approved in the United States in April 2018.[15][11]
{{cite web}}: CS1 maint: archived copy as title (link)